Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amneal Pharmaceuticals Inc
(NY:
AMRX
)
5.870
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 26, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amneal Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Amneal to Report Second Quarter 2023 Results on August 4, 2023
July 06, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter
July 03, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives U.S. FDA Complete Response Letter for IPX203
July 03, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals
June 15, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable
June 14, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at the 2023 Jefferies Healthcare Conference
May 24, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States
May 16, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports First Quarter 2023 Financial Results
May 05, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference
April 17, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance
April 17, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report First Quarter 2023 Results on May 5, 2023
April 12, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg
March 02, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Fourth Quarter and Full Year 2022 Financial Results
March 02, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023
January 31, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces Strategic European Partnership with Orion Corporation
January 04, 2023
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval
December 20, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Participate at Upcoming Investor Conferences
November 23, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States
November 22, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease
November 11, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Third Quarter 2022 Financial Results
November 04, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives FDA Approval for Leuprolide Acetate Injection
November 02, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory
October 31, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report Third Quarter 2022 Results on November 4, 2022
October 06, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States
October 03, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty
September 06, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease
August 31, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal supports Congress’ efforts to ensure essential medicines are Made in America
August 22, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal launches 4 new Generic products, including Vasopressin single-dose
August 11, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Reports Second Quarter 2022 Financial Results
August 05, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Appoints Deborah M. Autor to Board of Directors
August 03, 2022
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.